Products

CDM Insights
Oxford Brain Diagnostics
Neurology AI

See all 1 product →

About Oxford Brain Diagnostics

Oxford Brain Diagnostics (OBD) is a healthcare AI company pioneering quantitative brain biology through its patented Cortical Disarray Measurement (CDM®) technology. This innovative software analyzes standard MRI scans to provide an objective and quantifiable measure of neurodegeneration, offering a more precise way to assess brain health. The technology aims to revolutionize early and differential diagnosis of cognitive diseases, such as Alzheimer’s disease, frontotemporal dementia (FTD), and Parkinson’s disease, by identifying microscopic changes in the brain’s cellular structure that were previously only detectable post-mortem.

OBD’s technology supports both drug development and personalized patient care. For pharmaceutical and biotech companies, CDM® provides trusted measures from MRI scans, enabling more targeted and efficient clinical trials across multiple neurodegenerative conditions. For clinicians, it aids in diagnosis by revealing differential patterns of brain changes, accurately tracking disease progression, and supporting proactive brain health management. The company’s work is built on decades of expertise in brain pathology and imaging from its founders at the University of Oxford. CDM® has received Breakthrough Device Designation status from the U.S.

Focus Areas

neurodegenerative diseases Alzheimer's disease Parkinson's disease multiple sclerosis brain health assessment MRI analysis quantitative MRI biomarkers early diagnosis disease progression tracking drug development support

Business Intelligence

Technologycloud-native, Cortical Disarray Measurement (CDM®) technology, AI operating system

What Physicians Need to Know

Specialization: Neurodegeneration & Early Diagnosis
Oxford Brain Diagnostics specializes in the early diagnosis and assessment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Multiple Sclerosis. Their technology focuses on detecting microstructural changes in the brain before macrostructural alterations occur, offering insights into disease progression.
Key Differentiator: Cortical Disarray Measurement (CDM®)
Their proprietary Cortical Disarray Measurement (CDM®) software analyzes grey matter quality and uncovers insights based on changes in the brain at a cellular level. This technology has received Breakthrough Device Designation from the U.S. FDA and is FDA 510(k) cleared and UKCA approved.
Technology Stack: Advanced MRI Analysis
Oxford Brain Diagnostics utilizes advanced diffusion MRI analysis to assess brain microstructure. Their CDM® technology processes standard anatomical and diffusion MRI data from 1.5-tesla and 3-tesla scanners in a secure cloud environment.
Application: Drug Development Support & Clinical Trials
The company supports drug development by providing advanced MRI-based biomarkers for patient stratification, treatment monitoring, and therapeutic development in clinical trials for neurodegenerative diseases.
Focus: Neuroinflammation
Oxford Brain Diagnostics' technology is also being explored commercially by drug developers to study neuroinflammation, a key driver in the progression of diseases like Alzheimer's.
Physician Tip

For physicians, Oxford Brain Diagnostics offers CDM Insights, a software that provides a comprehensive assessment of brain changes by measuring microstructural changes in the cerebral cortex, cortical thickness, and regional volumes, along with white matter hyper-/hypointensity volume. This allows for early detection and ongoing monitoring of neurodegenerative conditions. The reports are quantitative, comprehensive, and compatible with standard MRI scanners, with results typically available within 12 hours of scan upload. The technology is not intended for isolated diagnosis or treatment decisions, but rather to provide crucial insights to support clinical evaluation and personalized patient care.

CDM Insights integrates with Picture Archiving and Communication Systems (PACS) to process standard anatomical and diffusion MRI data in a secure cloud environment. The company is ISO 13485 and ISO 27001 certified, and compliant with GDPR and HIPAA data privacy standards.

Products by Oxford Brain Diagnostics

1 product in the directory

CDM Insights
Oxford Brain Diagnostics
Neurology AI

Videos

News, demos, and interviews about Oxford Brain Diagnostics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Oxford Brain Diagnostics →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Oxford Brain Diagnostics' core technology, Cortical Disarray Measurement (CDM), is primarily focused on the early detection and monitoring of Alzheimer's disease by identifying subtle changes in brain structure. While the initial focus is on Alzheimer's, the underlying principles of cortical disarray may have implications for other neurodegenerative conditions like Parkinson's disease and Multiple Sclerosis, and the company is actively exploring these applications.
Oxford Brain Diagnostics utilizes a proprietary MRI analysis technique called Cortical Disarray Measurement (CDM) which quantifies subtle changes in cortical architecture that are not typically captured by standard radiological reads. This advanced analysis provides a more sensitive and objective measure of neurodegeneration, potentially enabling earlier diagnosis and more precise monitoring of disease progression than conventional methods.
Oxford Brain Diagnostics offers its Cortical Disarray Measurement (CDM) as a quantitative biomarker for use in drug development and clinical trials. This service helps pharmaceutical companies assess treatment efficacy, stratify patient populations, and monitor disease modification in studies related to Alzheimer's and other neurodegenerative diseases.
Oxford Brain Diagnostics' Cortical Disarray Measurement (CDM) has been validated in multiple research studies, demonstrating its ability to detect early signs of Alzheimer's disease and correlate with cognitive decline. The technology is designed to integrate with existing MRI infrastructure, aiming for high compliance and ease of use within clinical workflows.
Oxford Brain Diagnostics typically offers its services on a fee-for-service basis, with pricing models tailored to the specific needs of research institutions, pharmaceutical companies, and healthcare providers. They provide comprehensive support, including technical assistance and data interpretation, and actively seek partnerships with academic centers and industry leaders to advance neurodegeneration research and clinical implementation.
While Oxford Brain Diagnostics' primary focus is on structural changes measured by Cortical Disarray Measurement (CDM), neuroinflammation is a critical component of neurodegenerative diseases. The company acknowledges the importance of neuroinflammation and is actively exploring how CDM findings may correlate with or be complemented by other biomarkers of neuroinflammation to provide a more comprehensive brain health assessment.
Oxford Brain Diagnostics is a growing company with a strong scientific foundation and ongoing research and development. They are actively expanding their partnerships and clinical applications, indicating a stable trajectory and commitment to becoming a key player in the early diagnosis and monitoring of neurodegenerative diseases.

Related Companies

Spectrum Dynamics Medical is a pioneering medical device company focused on transforming nuclear medicine from analog to digital technology. They specialize in developing high-definition, solid-state based nuclear imaging technology, including digital SPECT (Single Photon Emission Computed Tomography) and SPECT/CT systems. Their products aim to meet the clinical needs and workflow demands of diagnostic imaging departments […]

Siemens Medical Solutions USA, Inc., operating as Siemens Healthineers USA, is a prominent medical technology company with a rich history spanning over 175 years, dedicated to pioneering breakthroughs in healthcare. As a subsidiary of the global Siemens Healthineers AG, the company offers a comprehensive portfolio that is central to clinical decision-making across the entire healthcare […]

Siemens Healthineers is a leading global medical technology company that pioneers breakthroughs in healthcare. The company focuses on medical technology and diagnostics, offering a wide range of products including imaging systems, laboratory diagnostics, and advanced therapies. Their innovations aim to improve patient outcomes and make healthcare more accessible and sustainable. Siemens Healthineers has a strong […]

Samsung Medison Co. is a global medical equipment company specializing in diagnostic imaging devices, particularly ultrasound systems. Established in 1985, the company has become the largest manufacturer of ultrasound systems in Korea. Samsung Medison integrates advanced technologies, including information technology, video signal processing, semiconductors, and communication, into its medical equipment. This integration enables the development […]

Philips Medical Systems Nederland B.V. is a key entity within Royal Philips, a leading global health technology company. The company focuses on improving people’s health and well-being through meaningful innovation, leveraging advanced technology and deep clinical and consumer insights to deliver integrated solutions. [6, 29] For physicians, this translates into a commitment to developing AI-enabled […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.